Increased risk of myopathy w/ concurrent use of cyclosporin, fibric acid derivatives, niacin or CYP450 3A4 inhibitors eg, erythromycin, azole antifungals. Increased plasma conc w/ CYP450 3A4 cytochrome inhibitors. Increased bioavailability w/ OATP1B1 inhibitors eg, cyclosporine. Concomitant use w/ erythromycin, clarithromycin, PIs, diltiazem HCl, itraconazole; CYP450 3A inducers eg, efavirenz, rifampicin; Mg- & Al-hydroxide-containing oral antacids; antipyrine, colestipol, digoxin, azithromycin, amlodipine, fusidic acid, ketoconazole, spironolactone, cimetidine.